von Hoch F, Neumann F J, Theiss W, Kastrati A, Schömig A
1. Medizinische Klinik, Technische Universität München, Germany.
Eur Heart J. 1995 May;16(5):640-6. doi: 10.1093/oxfordjournals.eurheartj.a060967.
A vascular haemostasis device has recently been introduced that allows percutaneous implantation of collagen plugs for haemostatic sealing of puncture sites even under full anticoagulation. This study assessed the incidence of access site complications after collagen plug implantation in patients with percutaneous coronary angioplasty (PTCA) or coronary stenting. Seventy-eight patients with coronary stenting and 231 patients with PTCA were included in a prospective randomized trial comparing collagen plug implantation to conventional haemostasis. Collagen plug implantation significantly reduced median manual compression times from 45 min (quartiles: 35 min, 51 min) to 5 min (4 min, 6 min) after stenting (P = 0.001) and from 27 min (20 min, 32 min) to 5 min (4 min, 6 min) after PTCA (P = 0.0001). After stenting, in 15 of the 37 patients with collagen implants, access site complications occurred (11 pseudoaneurysms, one arteriovenous fistula, three bleedings requiring blood transfusion, four local infections). The complication rate in the control group (17/41) was not significantly different (P = 0.88). After PTCA, three of the 114 control group patients suffered access site complications, while in the corresponding treatment group of 117 patients, complications occurred in 16 (seven pseudoaneurysms, one arteriovenous fistula, six infections, two femoral occlusions, one bleeding with nerve compression; P = 0.0049). In conclusion, the vascular haemostasis device allows rapid sealing of the vascular access site even under full anticoagulation. Its use after PTCA was however associated with increased access site complications, particularly infections, and even after coronary stenting, failed to reduce the incidence of access site complications.
最近推出了一种血管止血装置,即使在完全抗凝的情况下,也能经皮植入胶原蛋白栓用于穿刺部位的止血封闭。本研究评估了经皮冠状动脉腔内血管成形术(PTCA)或冠状动脉支架置入术患者植入胶原蛋白栓后穿刺部位并发症的发生率。一项前瞻性随机试验纳入了78例冠状动脉支架置入术患者和231例PTCA患者,比较胶原蛋白栓植入与传统止血方法。胶原蛋白栓植入显著缩短了支架置入术后的中位手动压迫时间,从45分钟(四分位数:35分钟,51分钟)降至5分钟(4分钟,6分钟)(P = 0.001),PTCA术后从27分钟(20分钟,32分钟)降至5分钟(4分钟,6分钟)(P = 0.0001)。支架置入术后,37例植入胶原蛋白栓的患者中有15例发生穿刺部位并发症(11例假性动脉瘤、1例动静脉瘘、3例需要输血的出血、4例局部感染)。对照组(17/41)的并发症发生率无显著差异(P = 0.88)。PTCA术后,114例对照组患者中有3例发生穿刺部位并发症,而在相应的117例治疗组患者中,有16例发生并发症(7例假性动脉瘤、1例动静脉瘘、6例感染、2例股动脉闭塞、1例伴有神经压迫的出血;P = 0.0049)。总之,这种血管止血装置即使在完全抗凝的情况下也能快速封闭血管穿刺部位。然而,PTCA术后使用该装置会增加穿刺部位并发症的发生率,尤其是感染,即使在冠状动脉支架置入术后,也未能降低穿刺部位并发症的发生率。